Danish biotech company Symphogen strengthens its patent position  

Symphogen gains a European patent on its Symphage antibody technology used for developing new drugs

Danish biotech company Symphogen has obtained a European patent on its unique Symphage technology for the development of antibodies which are used to develop new drugs. The patent has been issued to Symphogen’s research partner Boston University in the US, while Symphogen has exclusive rights to the patent worldwide and to previously granted US patents within the same patent family.


Copenhagen based Symphogen was established in 2000 with the aim of commercialising Symphage technology, which was invented by Professor Jacqueline Sharon of Boston University. Symphage is used to produce polyclonal antibody preparations known as symphobodies, whose commercial potential is thought to be substantial. The drugs it can create are expected to be advantageous against diseases such as allergy, infectious diseases, immunodeficiencies, transplant rejection and cancer.


Symphogen plans to start clinical testing of antibodies around the start of 2005. Investors in the company include the Danish-Swedish biotech fund Medicon Valley Capital, Essex Woodlands Health Ventures, Novo A/S, Lønmodtagernes Dyrtidsfond (the Employees Capital Pension Fund) , Vækstfonden (the Danish Growth Fund) and Danske Bank. The news is reported by daily broadsheet Berlingske Tidende and on Symphogen’s website.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×